

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
09 September 2022 (09.09.2022)



(10) International Publication Number
WO 2022/187275 A1

(51) International Patent Classification:

C07K 16/28 (2006.01) A61K 39/395 (2006.01)
C07K 16/30 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2022/018383

(22) International Filing Date:

01 March 2022 (01.03.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/155,304 02 March 2021 (02.03.2021) US
63/240,399 03 September 2021 (03.09.2021) US

(71) Applicant: NOVAROCK BIOTHERAPEUTICS, LTD.

[US/US]; 801 Charles Ewing Blvd., Ewing, New Jersey
08628 (US).

(72) Inventors: HUANG, Haichun; 4329 Crestwood Street,

Fremont, California 94538 (US). LEI, Ming; 20 Lockwood
Drive, Princeton, New Jersey 08540 (US). PEI, Yi; 1836
Glenwold Drive, Paoli, Pennsylvania 19301 (US). LI, Han;
1 Claire Dr., Newtown, Pennsylvania 18940 (US). LU,
Huarui; 6 Highfield Road, Skillman, New Jersey 08558
(US).

(74) Agent: BETTI, Christopher, J.; MORGAN, LEWIS &

BOCKIUS LLP, 110 North Wacker Drive, Suite 2800,
Chicago, Illinois 60606 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(54) Title: ANTIBODIES AGAINST CLAUDIN-6 AND USES THEREOF

(57) Abstract: The present disclosure provides antibodies and antibody fragments thereof that bind to human CLDN6. The disclosed antibodies may be used in antibody-based immunotherapy methods to direct a cytotoxic response against, or to target CLDN6 expressing cancers for destruction by an antibody drug conjugates.

WO 2022/187275 A1